Aliases & Classifications for Purpura

MalaCards integrated aliases for Purpura:

Name: Purpura 12 73 54 44 15 70
Purpuric Disorder 12


External Ids:

Disease Ontology 12 DOID:3326
MeSH 44 D011693
NCIt 50 C78787
SNOMED-CT 67 423902002
ICD10 32 D69.2
UMLS 70 C0034150

Summaries for Purpura

MalaCards based summary : Purpura, also known as purpuric disorder, is related to henoch-schoenlein purpura and thrombocytopenic purpura, autoimmune, and has symptoms including hemoptysis, pruritus and flushing. An important gene associated with Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are TGF-Beta Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Methotrexate and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include skin, bone marrow and spleen, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 73 Purpura (/ˈpɜːrpjʊərə/) is a condition of red or purple discolored spots on the skin that do not blanch... more...

Related Diseases for Purpura

Diseases related to Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1627)
# Related Disease Score Top Affiliating Genes
1 henoch-schoenlein purpura 33.1 MEFV CRP CD79A
2 thrombocytopenic purpura, autoimmune 32.5 THPO MPL ITGB3 ITGA2B ADAMTS13
3 thrombotic thrombocytopenic purpura 32.3 VWF THBD SERPINC1 ITGB3 F3 APOH
4 thrombocytopenia due to platelet alloimmunization 32.0 TNFSF13B THPO MPL ITGB3 ITGA2B
5 thrombotic microangiopathy 31.9 VWF THBD F3 ADAMTS13
6 hypersensitivity vasculitis 31.8 TNF MEFV IL6 CRP
7 evans' syndrome 31.7 THPO MPL ADAMTS13
8 protein c deficiency 31.6 THBD SERPINC1 PROC F2 APOH
9 fetal and neonatal alloimmune thrombocytopenia 31.6 ITGB3 ITGA2B
10 adult-onset still's disease 31.6 TNF MEFV IL6 CRP
11 hemolytic-uremic syndrome 31.2 VWF THBD F3 F2 ADAMTS13
12 chickenpox 31.1 TNF IL6 CRP
13 purpura fulminans 31.1 THBD SERPINC1 PROS1 PROCR PROC F3
14 protein s deficiency 31.0 THBD SERPINC1 PROS1 PROC F3 F2
15 heparin-induced thrombocytopenia 30.9 SERPINC1 F3
16 exanthem 30.8 TNF MEFV IL6 F3 F2 CRP
17 brucellosis 30.8 TNF MEFV IL6 CRP
18 thyroiditis 30.7 TNF IL6 CRP
19 hemolytic anemia 30.7 VWF TNFSF13B TNF THBD F3 F2
20 cryoglobulinemia 30.7 TNFSF13B TNF IL6 CD79A APOH
21 autoimmune disease 30.7 TNFSF13B TNF IL6 CRP CD79A APOH
22 vasculitis 30.7 VWF TNFSF13B TNF THBD MEFV IL6
23 malignant hypertension 30.7 VWF THBD ADAMTS13
24 appendicitis 30.7 TNF IL6 CRP
25 cardiogenic shock 30.6 TNF IL6
26 end stage renal disease 30.6 TNF THBD IL6 CRP
27 hepatitis a 30.6 TNF F3 F2
28 hemolytic uremic syndrome, atypical 1 30.6 VWF THBD F3 ADAMTS13
29 crohn's disease 30.5 TNF MEFV IL6 CRP
30 adult respiratory distress syndrome 30.5 TNF THBD IL6 F2
31 amyloidosis 30.5 TNF MEFV IL6 CRP
32 tonsillitis 30.5 TNF IL6 CD79A
33 orchitis 30.5 TNF IL6 CRP
34 enthesopathy 30.5 TNF MEFV CRP
35 eclampsia 30.5 TNF THBD SERPINC1 F2
36 polyarteritis nodosa 30.5 MEFV IL6 CRP APOH
37 intestinal perforation 30.5 TNF IL6 CRP
38 familial mediterranean fever 30.5 TNF MEFV IL6 CRP
39 acquired immunodeficiency syndrome 30.5 TNF IL6 CRP CD79A
40 factor viii deficiency 30.5 VWF SERPINC1 F3 F2
41 membranous nephropathy 30.5 TNF IL6 CD79A
42 toxic shock syndrome 30.4 TNF SERPINC1 IL6 F3 CRP
43 acquired thrombocytopenia 30.4 THPO MPL ITGA2B
44 hypersplenism 30.4 THPO SERPINC1 F2
45 erythema nodosum 30.4 TNF IL6 CRP
46 factor v deficiency 30.4 VWF F3 F2
47 intestinal obstruction 30.4 TNF IL6 CRP
48 hemangioma 30.4 VWF IL6 F3 F2
49 von willebrand's disease 30.3 VWF ITGA2B F3 F2 ADAMTS13
50 qualitative platelet defect 30.3 VWF THPO F3 F2

Graphical network of the top 20 diseases related to Purpura:

Diseases related to Purpura

Symptoms & Phenotypes for Purpura

UMLS symptoms related to Purpura:

hemoptysis; pruritus; flushing; icterus; petechiae of skin; skin manifestations; integumentary system signs and symptoms

MGI Mouse Phenotypes related to Purpura:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ADAMTS13 APOH CD79A CRP F2 F3
2 hematopoietic system MP:0005397 10.41 ADAMTS13 CD79A F3 IL6 ITGA2B ITGB3
3 immune system MP:0005387 10.39 ADAMTS13 CD79A CRP F2 F3 IL6
4 cardiovascular system MP:0005385 10.34 CRP F2 F3 IL6 ITGA2B ITGB3
5 cellular MP:0005384 10.32 CD79A F2 F3 IL6 ITGA2B ITGB3
6 mortality/aging MP:0010768 10.25 ADAMTS13 APOH CD79A F2 F3 IL6
7 embryo MP:0005380 10.19 F2 F3 ITGA2B ITGB3 MPL PROCR
8 integument MP:0010771 10.06 F2 F3 IL6 ITGA2B ITGB3 MEFV
9 liver/biliary system MP:0005370 10.02 CD79A IL6 ITGB3 MEFV PROC PROS1
10 nervous system MP:0003631 9.93 CD79A F2 F3 IL6 ITGA2B ITGB3
11 muscle MP:0005369 9.86 F2 F3 IL6 ITGB3 PROC PROS1
12 normal MP:0002873 9.61 ADAMTS13 CD79A F2 F3 ITGB3 MEFV
13 respiratory system MP:0005388 9.23 F2 F3 IL6 ITGB3 PROC THBD

Drugs & Therapeutics for Purpura

Drugs for Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
Azathioprine Approved Phase 4 446-86-6 2265
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
alemtuzumab Approved, Investigational Phase 4 216503-57-0
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Clarithromycin Approved Phase 4 81103-11-9 84029
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
Enoxolone Investigational Phase 4 471-53-4 18526330
16 Proton Pump Inhibitors Phase 4
17 Neuroprotective Agents Phase 4
18 Protective Agents Phase 4
19 Antioxidants Phase 4
20 Anti-Ulcer Agents Phase 4
21 Antacids Phase 4
22 Antimetabolites Phase 4
23 Tubulin Modulators Phase 4
24 Antimitotic Agents Phase 4
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Antimalarials Phase 4
28 retinol Phase 4
29 Retinol palmitate Phase 4
30 Arnica Phase 4
Caffeic acid Phase 4 331-39-5, 501-16-6 689043
32 Cytochrome P-450 CYP3A Inhibitors Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Autoantibodies Phase 4
35 Calcium, Dietary Phase 4
36 Trace Elements Phase 4
37 Nutrients Phase 4
38 Vitamins Phase 4
39 Micronutrients Phase 4
40 Calciferol Phase 4
41 Vasoconstrictor Agents Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
Pantoprazole Approved Phase 3 102625-70-7 4679
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
Dapsone Approved, Investigational Phase 3 80-08-0 2955
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
Chlorpheniramine Approved Phase 3 132-22-9, 113-92-8 2725
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 380)
# Name Status NCT ID Phase Drugs
1 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
2 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
3 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
4 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
5 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
6 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
7 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
8 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
9 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
10 Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety Completed NCT03222687 Phase 4 tacrolimus;prednisone
11 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
12 Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula;Non-active placebo control
13 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
14 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
15 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
16 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
17 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
18 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
19 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
20 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
21 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
22 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
23 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Recruiting NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
24 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
25 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
26 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
27 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
28 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
29 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
30 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
31 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
32 A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura Unknown status NCT03222843 Phase 3 Hetrombopag Olamine;matching placebo
33 Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial Unknown status NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
34 A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03443570 Phase 3 Rituximab;Bortezomib
35 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
36 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
37 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
38 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
39 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
40 A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP. Completed NCT00370331 Phase 3 eltrombopag;Placebo
41 A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00362349 Phase 3 IgNextGen 10%
42 EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study. Completed NCT00351468 Phase 3 eltrombopag olamine (SB-497115-GR)
43 A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
44 An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00116688 Phase 3
45 A Randomized Trial of Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
46 A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura Completed NCT00451594 Phase 3 Dexamethasone;Prednisolone
47 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
48 A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Completed NCT00102323 Phase 3 Placebo
49 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
50 Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3 Octagam 10%

Search NIH Clinical Center for Purpura

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Epoprostenol Sodium

Cochrane evidence based reviews: purpura

Genetic Tests for Purpura

Anatomical Context for Purpura

MalaCards organs/tissues related to Purpura:

Skin, Bone Marrow, Spleen, Endothelial, T Cells, Neutrophil, Myeloid

Publications for Purpura

Articles related to Purpura:

(show top 50) (show all 23237)
# Title Authors PMID Year
Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. 61 54
20056836 2010
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report. 54 61
20181224 2010
[Henoch-Shönlein purpura]. 54 61
19345173 2009
Childhood Henoch-Schonlein nephritis: a multivariate analysis of clinical features and renal morphology at disease onset. 61 54
19377254 2009
Vasculitic IgA nephropathy: prognosis and outcome. 61 54
19342865 2009
Familial clusturing of Henoch-Schönlein purpura or IgA nephropathy: genetic background or environmental triggers? 54 61
19067882 2008
IgA nephropathy and Henoch-Schönlein purpura nephritis. 61 54
18332712 2008
The diagnostic value of IgA deposition in Henoch-Schönlein purpura. 61 54
18304186 2008
Splenic peliosis in the course of IgA nephropathy. 61 54
17885767 2007
Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. 61 54
17551657 2007
Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. 61 54
17699418 2007
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 61 54
17164950 2006
Fatal relapse of thrombotic thrombocytopaenic purpura after cardiac surgery in patient with congenital absence of vWF-cleaving protease activity. 61 54
16421154 2006
Thrombotic thrombocytopaenic purpura in HIV-infected patients. 61 54
16105187 2005
[Effect of danshao granule on serum superoxide dismutase activity and malonyldialdehyde content in children with Henoch-Schonlein purpura nephritis]. 61 54
14714360 2003
A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura. 61 54
12656756 2003
Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. 54 61
12453297 2002
Acute glomerulonephritis. 61 54
10798062 1999
IgA nephropathy--human disease and animal model. 54 61
9154653 1997
Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. 61 54
9126006 1997
Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis. 54 61
9046734 1997
Inherited prethrombotic disorders and infectious purpura. 54 61
8822583 1996
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. 54 61
8639762 1996
IgA-associated renal diseases. 61 54
8744534 1996
Serum anti-streptococcal IgA, IgG and IgM antibodies in IgA-associated diseases. 54 61
8503268 1993
Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura. 61 54
1445457 1992
Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. 61 54
1430582 1992
Regional variation in C4 phenotype in patients with IgA nephropathy. 54 61
2329414 1990
[Schönlein-Henoch purpura and IgA nephropathy. A common pathogenetic cause?]. 61 54
2327670 1990
Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. 61
33594951 2021
Ibrutinib-induced acute kidney injury via interstitial nephritis. 61
33567947 2021
Clinical relevance of neutrophil-to-lymphocyte ratio and mean platelet volume in pediatric Henoch-Schonlein Purpura: a meta-analysis. 61
33412982 2021
Biopsy-proven Henoch-Schönlein purpura nephritis: a single center experience. 61
33089378 2021
Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. 61
33660913 2021
Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study. 61
33186517 2021
Different Chinese herbal medicine therapy for idiopathic thrombocytopenic purpura: A protocol for systematic review and Bayesian network meta-analysis. 61
33787633 2021
COVID Purpura (Toes) Case Series: A Chilblains-Like Vasculopathy. 61
33156022 2021
The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. 61
33716293 2021
Hematopoietic stem cell transplantation in an infant with dedicator of cytokinesis 8 (DOCK8) deficiency associated with systemic lupus erythematosus: A case report. 61
33787566 2021
Purpura fulminans: How varicella zoster can result in acquired protein S deficiency. 61
33342033 2021
Palisaded neutrophilic granulomatous dermatitis, interstitial granulomatous dermatitis and IgA vasculitis associated with incomplete Sjögren's syndrome. 61
33406284 2021
Myocarditis and intracardiac thrombus due to Henoch-Schönlein purpura: case report and literature review. 61
32789615 2021
A Bladder Mass in a Patient with Henoch-Schönlein Purpura. 61
33321145 2021
A detailed analysis of the distribution, morphology, and histopathology of complex purpura in hospitalized patients: A case series of 68 patients. 61
32376433 2021
Spinal Cord Infarction in a Patient with Immune Thrombocytopenic Purpura. 61
33508727 2021
Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases. 61
33211391 2021
Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura. 61
33184803 2021
Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. 61
31964209 2021
Thrombotic thrombocytopenic purpura (TTP) response following COVID-19 infection: Implications for the ADAMTS-13-von Willebrand factor axis. 61
33382919 2021
Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19. 61
33359476 2021

Variations for Purpura

Expression for Purpura

Search GEO for disease gene expression data for Purpura.

Pathways for Purpura

Pathways related to Purpura according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.22 TNF IL6 F2 CRP
Show member pathways
Show member pathways
Show member pathways
9 11.92 VWF ITGB3 ITGA2B F2
11 11.8 TNF THBD IL6 F3
Show member pathways
14 11.64 TNF THBD IL6
15 11.57 TNFSF13B TNF IL6
16 11.44 VWF ITGB3 ITGA2B F2
17 11.42 ITGB3 ITGA2B IL6
19 10.93 TNF IL6 CRP
21 10.81 PROS1 PROC F2

GO Terms for Purpura

Cellular components related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.81 TNF THBD PROCR MPL ITGB3 ITGA2B
2 external side of plasma membrane GO:0009897 9.8 TNF THBD ITGA2B F2 CD79A
3 extracellular region GO:0005576 9.8 VWF TNFSF13B TNF THPO SERPINC1 PROS1
4 collagen-containing extracellular matrix GO:0062023 9.77 VWF SERPINC1 F3 F2 APOH
5 endoplasmic reticulum lumen GO:0005788 9.65 SERPINC1 PROC IL6 F2 ADAMTS13
6 blood microparticle GO:0072562 9.62 SERPINC1 PROS1 ITGA2B F2
7 extracellular space GO:0005615 9.5 VWF TNFSF13B TNF THPO THBD SERPINC1

Biological processes related to Purpura according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.9 SERPINC1 PROC IL6 F2
2 extracellular matrix organization GO:0030198 9.89 VWF TNF ITGB3 ITGA2B ADAMTS13
3 positive regulation of protein phosphorylation GO:0001934 9.88 TNF THPO ITGB3 F2
4 leukocyte migration GO:0050900 9.88 TNF THBD PROS1 ITGB3 F2
5 platelet degranulation GO:0002576 9.77 VWF PROS1 ITGB3 ITGA2B APOH
6 positive regulation of interleukin-8 production GO:0032757 9.73 TNF IL6 F3
7 platelet activation GO:0030168 9.72 VWF ITGB3 IL6 F2 ADAMTS13
8 platelet aggregation GO:0070527 9.71 MPL ITGB3 ITGA2B
9 acute-phase response GO:0006953 9.7 IL6 F2 CRP
10 positive regulation of JAK-STAT cascade GO:0046427 9.69 TNF IL6 F2
11 blood coagulation GO:0007596 9.65 VWF THBD SERPINC1 PROS1 PROCR PROC
12 blood coagulation, intrinsic pathway GO:0007597 9.63 VWF F2 APOH
13 regulation of blood coagulation GO:0030193 9.61 SERPINC1 F2 APOH
14 negative regulation of platelet activation GO:0010544 9.59 THBD F2
15 negative regulation of coagulation GO:0050819 9.58 PROCR PROC
16 negative regulation of fibrinolysis GO:0051918 9.58 THBD F2 APOH
17 vascular endothelial growth factor production GO:0010573 9.57 TNF IL6
18 negative regulation of blood coagulation GO:0030195 9.56 THBD PROS1 PROC APOH
19 thrombopoietin-mediated signaling pathway GO:0038163 9.55 THPO MPL
20 negative regulation of lipid storage GO:0010888 9.46 TNF ITGB3 IL6 CRP
21 hemostasis GO:0007599 9.28 VWF THBD SERPINC1 PROS1 PROCR PROC

Molecular functions related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.73 THBD PROS1 PROC F2 CRP ADAMTS13
2 cytokine activity GO:0005125 9.62 TNFSF13B TNF THPO IL6
3 identical protein binding GO:0042802 9.61 VWF TNF SERPINC1 MEFV ITGB3 ITGA2B
4 fibrinogen binding GO:0070051 9.16 ITGB3 ITGA2B
5 protease binding GO:0002020 9.02 VWF TNF SERPINC1 ITGB3 F3

Sources for Purpura

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....